OSL

About OSL

OncoSil Medical Limited (OSL) is an ASX-listed medical device company with a focus on localised treatments for patients with pancreatic and liver cancer. The company's lead product, OncoSil, is a medical device that delivers targeted radioactive isotope (Phosphorous-32) directly into a patient's pancreatic tumours via an endoscopic ultrasound. This treatment, known as brachytherapy, is intended to deliver more concentrated and localized radiation. Over the past year, the company has made significant progress in its operations, including the first commercial treatment of the OncoSil device in Europe.

Buy Australian shares starting with OSL. Invest today with a CHESS-sponsored investing platform!

Announcements

What does OncoSil Medical Limited (OSL) do?

Oh, nothing major, just trying to fight cancer. 

Headquartered in North Sydney, OncoSil Medical Limited is a medical device company focused on Interventional Oncology (IO), a minimally invasive form of oncology.

The company aims to make life easier for people enduring pancreatic cancer with OncoSil, its flagship brachytherapy device. OncoSil has been designed for implantation directly into a patient’s pancreatic tumours via an endoscopic ultrasound.

Compared to external beam radiotherapy, the OncoSil device can deliver higher doses of radiation while sparing damage to surrounding tissue and critical organs after implantation.

OncoSil Medical took its first step towards revenue generation in October 2020, when it achieved its first sale to a patient in New Zealand. However, COVID-19 disrupted the company’s commercialisation strategy. They're currently hard at work on progressing sales and adoption across Europe, the United States, the Middle East and Asia Pacific.

Is OncoSil Medical a profitable company?

No, OncoSil Medical is not a profitable company. 

The company reported revenue of A$213k in FY2021, but prior to this had not earned any revenue since FY2012. The company also recorded net losses between FY2012 and FY2021. In FY2019, FY2020 and FY2021 alone, the company’s net losses amounted to A$8.57m, A$4.26m and A$10.43m, respectively.

As of April 2022, the company holds A$6.6m of cash on its books.

Is OSL stock a buy?

Some investors believe it's a good time to buy OSL stock.

On 13 April 2022, OncoSil Medical announced the first commercial pancreas cancer treatment using the OncoSil device at The Hospital Universitario de Fuenlabrada in Madrid, Spain. The company also announced that ten more hospitals across Spain had been trained to use the OncoSil device. Off this news, the OSL stock price leapt almost 75% from A$0.04 to A$0.07.

However, other investors won’t go near OSL stock for now as the company remains unprofitable and has plenty more regulatory hoops to jump through.

Does OSL stock pay dividends?

OSL stock has no history of distributing dividends. The company has made no announcements to pay dividends this financial year or in the future.

Who owns OSL stock?

At 80.2% of the total float, the general public holds the majority of OSL stock. Individual insiders come second, holding 11.1%.

Some of OSL stock’s most significant owners include Netwealth Investments Ltd (3.04%), Rojo Nero Capital Pty Ltd (2.36%), Gregory Harris (1.98%), Roger Aston (1.6%) and Henderson Family Pty Ltd (1.18%).

Some individual insiders with significant holdings include Non-Executive Director Otto Buttula (3.79%), Global Sales and Marketing Director Michael Warrener (0.88%), CEO Nigel Lange (0.72%), Chairman of the Board Christopher Roberts (0.72%) and CFO Karl Pechmann (0.11%).

How do I buy OSL stock?

Stake offers a quick and easy way to purchase OSL shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is a CHESS sponsored investing platform, meaning that when you buy ASX shares, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding OSL, sign up today.